Navamedic

Navamedic ASA: Letter received from the Norwegian Financial Supervisory Authority

Oslo, March 28 2025. Navamedic ASA (OSE ticker "NAVA") has received a letter

from the Norwegian Financial Supervisory Authority (the "NFSA") regarding the

accounting of Navamedic's loans to Observe Medical ASA in relation to the

Company's annual financial statements for 2023.

The NFSA's assessment is that there are misstatements in the annual financial

statements for 2023 and in the interim financial statements for 2024 related to

the Company's accounting of the two loans Navamedic has to Observe Medical ASA,

interest on those loans and the information provided in the notes to the

accounts.

The Company will assess the information received and implement any required

corrections of the accounts.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail:

Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail:

This information is considered to be inside information pursuant to the EU

Market Abuse Regulation and is subject to the disclosure requirements pursuant

to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Lars Hjarrand, CFO of the

Company, on 28 March 2025 at 14:24 hours CET on behalf of the Company.

About Navamedic:

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's

quality of life by being a reliable supplier of high-quality prescription,

consumer health, and hospital products to hospitals and pharmacies. Our growing

product portfolio has been carefully selected to meet current public health

concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to

empower people to live healthier and more fulfilling lives. What sets us apart

is our deep-rooted commitment to understanding the needs and requirements of the

countries where we are present. Our local insight and competence enable us to

understand the specific needs of each country where we operate and ultimately to

gain market access. This makes us a preferred partner for international

companies expanding their footprint across the Nordics and Benelux regions,

through either in-licensing or out-licensing. Navamedic has been listed on the

Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo,

Norway. For more information, please visit Navamedic.com.

AI Terminal